MiMedx集團 MDXG 深 滬
已收盤 10-31 16:00:00 美东时间
7.65
+0.250
+3.38%
華盛通- 最 高7.815
- 今 開7.35
- 成交量 280.05万股
- 最 低 7.275
- 昨 收 7.40
- 總市值 11.32亿
- 52周最高 10.14
- 市盈率 靜 26.88
- 換手率 1.89%
- 52周最低 5.79
- 委 比 -26.23%
- 總股本 1.48亿
- 歷史最高 18.25
- 量 比 1.72
- 振 幅 7.30%
- 歷史最低 0.83
- 每 手 1
- 風險率 1.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MiMedx Group shares are trading higher after the company reported Q3 results above estimates.
MiMedx Group shares are trading higher after the company reported Q3 results ab...
10-30 19:42
Earnings Scheduled For October 29, 2025
Companies Reporting Before The Bell • OppFi (NYSE:OPFI) is expected to report q...
10-29 19:11
MIMEDX Announces Launch of EPIXPRESS®
MiMedx Group announced the launch of EPIXPRESS, a new advanced wound care solution. This lyophilized placental allograft features a fenestrated design to enhance fluid movement, improving treatment for hard-to-heal wounds such as diabetic foot ulcers and venous leg ulcers. As part of the company’s AWC portfolio, EPIXPRESS continues MIMEDX’s commitment to innovative, market-driven solutions for wound management.
10-06 13:28
MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall
MiMedx Group announced its participation in the SAWC Fall meeting in Las Vegas, showcasing its advanced wound care portfolio at booth 511. The company will host a sponsored lunch symposium titled "Change is Inevitable: Mastering the Art of Wound Healing in an Evolving Landscape" on September 4, featuring experts Paul Kim, Nicolas Mouawad, and Scott Boynton. Additionally, six clinical posters will be presented, focusing on wound care innovations. ...
09-03 12:00
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
MDxHealth在2025年第二季度实现了20%的收入增长，达到2660万美元，并通过收购Bio-Techne的ExoDx业务，进一步扩展其前列腺癌液基诊断能力，预计将在2025年第四季度提升调整后EBITDA。
08-05 20:01
What to Expect from Ardelyx's Earnings
Ardelyx (NASDAQ:ARDX) is gearing up to announce its quarterly earnings on Monda...
08-02 04:01
Cantor Fitzgerald Maintains Overweight on MiMedx Group, Raises Price Target to $12
Cantor Fitzgerald analyst Ross Osborn maintains MiMedx Group (NASDAQ:MDXG) with a Overweight and raises the price target from $11 to $12.
07-31 20:54
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers OSR Holdings (NASDAQ:OSRH) stock rose 21.4% to $1.05 during Wednesday'...
07-31 05:06
MiMedx Group And Vaporox Collaborate To Co-Promote And Co-Market Their Wound Care Offerings
MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") and Vaporox, Inc. ("Vaporox") today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part
07-30 20:04
MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
MIMEDX and Vaporox have entered a collaboration to co-promote and co-market their wound care solutions. MIMEDX has invested in Vaporox and gained exclusivity rights. Vaporox's Vaporous Hyperoxia Therapy (VHT) device treats chronic wounds using ultrasonic mist and concentrated oxygen, receiving FDA clearance for nine wound types. Both companies aim to expand market presence and improve patient outcomes through this partnership.
07-30 12:00
